{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:45:06Z","timestamp":1792460706561,"version":"4.5.0"},"reference-count":114,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key R&amp;D Program of China","award":["2022YFA1303600"],"award-info":[{"award-number":["2022YFA1303600"]}]},{"name":"National Key R&amp;D Program of China","award":["cstc2021jcyj-msxmX0298"],"award-info":[{"award-number":["cstc2021jcyj-msxmX0298"]}]},{"name":"National Key R&amp;D Program of China","award":["cstc2020jcyj-msxmX0764"],"award-info":[{"award-number":["cstc2020jcyj-msxmX0764"]}]},{"name":"National Key R&amp;D Program of China","award":["cstc2020jscx-dxwtBX0022"],"award-info":[{"award-number":["cstc2020jscx-dxwtBX0022"]}]},{"name":"National Key R&amp;D Program of China","award":["D20028"],"award-info":[{"award-number":["D20028"]}]},{"name":"National Key R&amp;D Program of China","award":["202104"],"award-info":[{"award-number":["202104"]}]},{"name":"National Key R&amp;D Program of China","award":["W0049"],"award-info":[{"award-number":["W0049"]}]},{"name":"Natural Science Foundation of Chongqing","award":["2022YFA1303600"],"award-info":[{"award-number":["2022YFA1303600"]}]},{"name":"Natural Science Foundation of Chongqing","award":["cstc2021jcyj-msxmX0298"],"award-info":[{"award-number":["cstc2021jcyj-msxmX0298"]}]},{"name":"Natural Science Foundation of Chongqing","award":["cstc2020jcyj-msxmX0764"],"award-info":[{"award-number":["cstc2020jcyj-msxmX0764"]}]},{"name":"Natural Science Foundation of Chongqing","award":["cstc2020jscx-dxwtBX0022"],"award-info":[{"award-number":["cstc2020jscx-dxwtBX0022"]}]},{"name":"Natural Science Foundation of Chongqing","award":["D20028"],"award-info":[{"award-number":["D20028"]}]},{"name":"Natural Science Foundation of Chongqing","award":["202104"],"award-info":[{"award-number":["202104"]}]},{"name":"Natural Science Foundation of Chongqing","award":["W0049"],"award-info":[{"award-number":["W0049"]}]},{"name":"111 Project","award":["2022YFA1303600"],"award-info":[{"award-number":["2022YFA1303600"]}]},{"name":"111 Project","award":["cstc2021jcyj-msxmX0298"],"award-info":[{"award-number":["cstc2021jcyj-msxmX0298"]}]},{"name":"111 Project","award":["cstc2020jcyj-msxmX0764"],"award-info":[{"award-number":["cstc2020jcyj-msxmX0764"]}]},{"name":"111 Project","award":["cstc2020jscx-dxwtBX0022"],"award-info":[{"award-number":["cstc2020jscx-dxwtBX0022"]}]},{"name":"111 Project","award":["D20028"],"award-info":[{"award-number":["D20028"]}]},{"name":"111 Project","award":["202104"],"award-info":[{"award-number":["202104"]}]},{"name":"111 Project","award":["W0049"],"award-info":[{"award-number":["W0049"]}]},{"name":"Key Laboratory of Molecular Biology on Infectious Diseases, the Ministry of Education, Chongqing Medical University","award":["2022YFA1303600"],"award-info":[{"award-number":["2022YFA1303600"]}]},{"name":"Key Laboratory of Molecular Biology on Infectious Diseases, the Ministry of Education, Chongqing Medical University","award":["cstc2021jcyj-msxmX0298"],"award-info":[{"award-number":["cstc2021jcyj-msxmX0298"]}]},{"name":"Key Laboratory of Molecular Biology on Infectious Diseases, the Ministry of Education, Chongqing Medical University","award":["cstc2020jcyj-msxmX0764"],"award-info":[{"award-number":["cstc2020jcyj-msxmX0764"]}]},{"name":"Key Laboratory of Molecular Biology on Infectious Diseases, the Ministry of Education, Chongqing Medical University","award":["cstc2020jscx-dxwtBX0022"],"award-info":[{"award-number":["cstc2020jscx-dxwtBX0022"]}]},{"name":"Key Laboratory of Molecular Biology on Infectious Diseases, the Ministry of Education, Chongqing Medical University","award":["D20028"],"award-info":[{"award-number":["D20028"]}]},{"name":"Key Laboratory of Molecular Biology on Infectious Diseases, the Ministry of Education, Chongqing Medical University","award":["202104"],"award-info":[{"award-number":["202104"]}]},{"name":"Key Laboratory of Molecular Biology on Infectious Diseases, the Ministry of Education, Chongqing Medical University","award":["W0049"],"award-info":[{"award-number":["W0049"]}]},{"name":"CQMU Program for Youth Innovation in Future Medicine","award":["2022YFA1303600"],"award-info":[{"award-number":["2022YFA1303600"]}]},{"name":"CQMU Program for Youth Innovation in Future Medicine","award":["cstc2021jcyj-msxmX0298"],"award-info":[{"award-number":["cstc2021jcyj-msxmX0298"]}]},{"name":"CQMU Program for Youth Innovation in Future Medicine","award":["cstc2020jcyj-msxmX0764"],"award-info":[{"award-number":["cstc2020jcyj-msxmX0764"]}]},{"name":"CQMU Program for Youth Innovation in Future Medicine","award":["cstc2020jscx-dxwtBX0022"],"award-info":[{"award-number":["cstc2020jscx-dxwtBX0022"]}]},{"name":"CQMU Program for Youth Innovation in Future Medicine","award":["D20028"],"award-info":[{"award-number":["D20028"]}]},{"name":"CQMU Program for Youth Innovation in Future Medicine","award":["202104"],"award-info":[{"award-number":["202104"]}]},{"name":"CQMU Program for Youth Innovation in Future Medicine","award":["W0049"],"award-info":[{"award-number":["W0049"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Eradication of cccDNA is an ideal goal of chronic hepatitis B (CHB) therapy. Understanding the changes in the cccDNA pool during therapy provides a basis for developing CHB treatment strategies. On the other hand, the shift in the balance of the cccDNA pool following therapies allowed researchers to investigate the dynamics of cccDNA. Central to the description of cccDNA dynamics is a parameter called cccDNA half-life. CccDNA half-life is not an intrinsic property of cccDNA molecules, but a description of an observed phenomenon characterized by cccDNA pool decline. Since cccDNA has to be in the nuclei of host cells to function, the half-life of cccDNA is determined by the state and destiny of the host cells. The major factors that drive cccDNA decay include noncytopathic effects and hepatocyte turnover (death and division). In some cases, the determining factor is not the half-life of cccDNA itself, but rather the half-life of the hepatocyte. The main purpose of this review is to analyze the major factors affecting cccDNA half-life and determine the areas requiring further study. In addition, the discrepancy in cccDNA half-life between short-term and long-term nucleot(s)ide analog (NUC) therapy was reported. Hypotheses were proposed to explain the multi-phasic decline of cccDNA during NUC therapy, and a framework based on cccDNA dynamics was suggested for the consideration of various anti-HBV strategies.<\/jats:p>","DOI":"10.3390\/microorganisms11030600","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T03:00:38Z","timestamp":1677553238000},"page":"600","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Dynamics of Hepatitis B Virus Covalently Closed Circular DNA: A Mini-Review"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9869-659X","authenticated-orcid":false,"given":"Jie-Li","family":"Hu","sequence":"first","affiliation":[{"name":"Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing 400016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Long","family":"Huang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing 400016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: From discovery to regulatory approval","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/jvh.13126","article-title":"Roadmap to functional cure of chronic hepatitis B: An expert consensus","volume":"26","author":"Ning","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug de-velopment?","volume":"76","author":"Wong","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Wei, L., and Ploss, A. (2021). Mechanism of Hepatitis B Virus cccDNA Formation. Viruses, 13.","DOI":"10.3390\/v13081463"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"104824","DOI":"10.1016\/j.antiviral.2020.104824","article-title":"Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential","volume":"180","author":"Xia","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1002\/hep.29479","article-title":"Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B","volume":"66","author":"Hong","year":"2017","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2017.12.006","article-title":"Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop","volume":"150","author":"Block","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","article-title":"Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections","volume":"75","author":"Martinez","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lim, S.G., Baumert, T.F., Boni, C., Gane, E., Levrero, M., Lok, A.S., Maini, M.K., Terrault, N.A., and Zoulim, F. (2023). The scientific basis of combination therapy for chronic hepatitis B functional cure. Nat. Rev. Gastroenterol. Hepatol., 1\u201316.","DOI":"10.1038\/s41575-022-00724-5"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New Approaches to Chronic Hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Degasperi, E., Anolli, M.P., and Lampertico, P. (2022). Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies. Viruses, 14.","DOI":"10.3390\/v14112404"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jhep.2017.11.036","article-title":"Inhibition of hepatitis B virus gene expression: A step towards functional cure","volume":"68","author":"Zoulim","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.molmed.2022.06.002","article-title":"New strategies for the treatment of chronic hepatitis B","volume":"28","author":"Mak","year":"2022","journal-title":"Trends Mol. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: Towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev-med-080119-103356","article-title":"New Therapeutics for Hepatitis B: The Road to Cure","volume":"72","author":"Naggie","year":"2021","journal-title":"Annu. Rev. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.3389\/fimmu.2019.02308","article-title":"Toward a Functional Cure for Hepatitis B: The Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response","volume":"10","author":"Ma","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1073\/pnas.93.9.4398","article-title":"Viral dynamics in hepatitis B virus infection","volume":"93","author":"Nowak","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100480","DOI":"10.1016\/j.jhepr.2022.100480","article-title":"Assessing immunological and virological responses in the liver: Implications for the cure of chronic hepatitis B virus infection","volume":"4","author":"Boettler","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"17780","DOI":"10.1073\/pnas.0508913102","article-title":"Dynamics of hepatitis B virus clearance in chimpanzees","volume":"102","author":"Murray","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jhep.2016.05.014","article-title":"Decay of ccc-DNA marks per-sistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients","volume":"65","author":"Boyd","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1074-7613(00)80295-2","article-title":"Intracellular Inactivation of the Hepatitis B Virus by Cytotoxic T Lymphocytes","volume":"4","author":"Guidotti","year":"1996","journal-title":"Immunity"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","article-title":"Interferon-gamma and Tumor Necrosis Factor-alpha Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis","volume":"150","author":"Xia","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.284.5415.825","article-title":"Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection","volume":"284","author":"Guidotti","year":"1999","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1128\/JVI.01587-08","article-title":"The amount of hepatocyte turnover that oc-curred during resolution of transient hepadnavirus infections was lower when virus replication was inhibited with entecavir","volume":"83","author":"Mason","year":"2009","journal-title":"J. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1073\/pnas.91.9.3764","article-title":"Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice","volume":"91","author":"Guidotti","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Liu, F., Campagna, M., Qi, Y., Zhao, X., Guo, F., Xu, C., Li, S., Li, W., Block, T.M., and Chang, J. (2013). Alpha-Interferon Suppresses Hepadnavirus Transcription by Altering Epigenetic Modification of cccDNA Minichromosomes. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003613"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41575-020-0342-4","article-title":"Liver regeneration: Biological and pathological mechanisms and implications","volume":"18","author":"Michalopoulos","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"8321","DOI":"10.1128\/jvi.68.12.8321-8330.1994","article-title":"Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks","volume":"68","author":"Fourel","year":"1994","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6356","DOI":"10.1128\/JVI.76.12.6356-6363.2002","article-title":"Half-life of the duck hepatitis B virus co-valently closed circular DNA pool in vivo following inhibition of viral replication","volume":"76","author":"Addison","year":"2002","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1128\/JVI.75.1.311-322.2001","article-title":"Kinetics of Hepadnavirus Loss from the Liver during Inhibition of Viral DNA Synthesis","volume":"75","author":"Zhu","year":"2001","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.gastro.2007.11.002","article-title":"T Cells Redirected Against Hepatitis B Virus Surface Proteins Eliminate Infected Hepatocytes","volume":"134","author":"Bohne","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2013.04.047","article-title":"T Cells Expressing a Chimeric Antigen Receptor That Binds Hepatitis B Virus Envelope Proteins Control Virus Replication in Mice","volume":"145","author":"Krebs","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1172\/JCI120228","article-title":"T cell receptor grafting allows virological control of hepatitis B virus infection","volume":"129","author":"Wisskirchen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jhep.2018.08.012","article-title":"Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels","volume":"69","author":"Ko","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1423-0127-18-96","article-title":"Dynamics of HBV cccDNA expression and tran-scription in different cell growth phase","volume":"18","author":"Chong","year":"2011","journal-title":"J. Biomed. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"100514","DOI":"10.1016\/j.jhepr.2022.100514","article-title":"Mitosis of hepatitis B virus-infected cells in vitro results in uninfected daughter cells","volume":"4","author":"Tu","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e01391-17","DOI":"10.1128\/JVI.01391-17","article-title":"Distribution of Hepatitis B Virus Nuclear DNA","volume":"92","author":"Li","year":"2018","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/jhep.2000.8701","article-title":"Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus repli-cation by adefovir in vitro do not lead to reduction of the closed circular DNA","volume":"32","author":"Dandri","year":"2000","journal-title":"Hepatology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/hep.23611","article-title":"In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice","volume":"52","author":"Lutgehetmann","year":"2010","journal-title":"Hepatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/gutjnl-2016-312162","article-title":"Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo","volume":"67","author":"Allweiss","year":"2018","journal-title":"Gut"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/archinte.1961.03620030023003","article-title":"\u201cLifespan\u201d of liver cells. Autoradio-graphic study using tritiated thymidine in normal, cirrhotic, and partially hepatectomized rats","volume":"107","author":"Macdonald","year":"1961","journal-title":"Arch. Intern. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1034\/j.1600-0676.2002.01702.x","article-title":"Cell proliferation and renewal of normal hepatocytes and bile duct cells in adult mouse liver","volume":"22","author":"Magami","year":"2002","journal-title":"Liver Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"eabc4346","DOI":"10.1126\/science.abc4346","article-title":"Proliferation tracing reveals regional hepatocyte generation in liver homeostasis and repair","volume":"371","author":"He","year":"2021","journal-title":"Science"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"eabb1625","DOI":"10.1126\/science.abb1625","article-title":"Liver homeostasis is maintained by midlobular zone 2 hepatocytes","volume":"371","author":"Wei","year":"2021","journal-title":"Science"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1073\/pnas.82.10.3262","article-title":"Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: Subdivision of S phase","volume":"82","author":"Celis","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/j.1460-2075.1985.tb03679.x","article-title":"Changes in the nuclear distribution of cyclin (PCNA) but not its synthesis depend on DNA replication","volume":"4","author":"Bravo","year":"1985","journal-title":"EMBO J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1083\/jcb.105.4.1549","article-title":"Existence of two populations of cyclin\/proliferating cell nuclear antigen during the cell cycle: Association with DNA replication sites","volume":"105","author":"Bravo","year":"1987","journal-title":"J. Cell Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-0676.1994.tb00048.x","article-title":"Immunohistochemical analysis of S-phase cells in normal human and rat liver by PC10 monoclonal antibody","volume":"14","author":"Mancini","year":"1994","journal-title":"Liver Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/BF02361242","article-title":"Evaluation of hepatic proliferative activity in chronic liver diseases and hepatocellular carcinomas by proliferating cell nuclear antigen (PCNA) immunohisto-chemical staining of methanol-fixed tissues","volume":"29","author":"Nakajima","year":"1994","journal-title":"J. Gastroenterol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Mason, W.S., Jilbert, A.R., and Litwin, S. (2021). Hepatitis B Virus DNA Integration and Clonal Expansion of Hepatocytes in the Chronically Infected Liver. Viruses, 13.","DOI":"10.3390\/v13020210"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"K\u00f6ck, J., R\u00f6sler, C., Zhang, J.-J., Blum, H.E., Nassal, M., and Thoma, C. (2010). Generation of Covalently Closed Circular DNA of Hepatitis B Viruses via Intracellular Recycling Is Regulated in a Virus Specific Manner. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001082"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"12472","DOI":"10.1128\/JVI.01123-07","article-title":"Characterization of the Intracellular Deproteinized Relaxed Circular DNA of Hepatitis B Virus: An Intermediate of Covalently Closed Circular DNA Formation","volume":"81","author":"Guo","year":"2007","journal-title":"J. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.1128\/JVI.02721-06","article-title":"Formation of Hepatitis B Virus Covalently Closed Circular DNA: Removal of Genome-Linked Protein","volume":"81","author":"Gao","year":"2007","journal-title":"J. Virol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.omtn.2023.02.001","article-title":"Depleting hepatitis B virus relaxed circular DNA is necessary for resolution of infection by CRISPR-Cas9","volume":"31","author":"Kostyushev","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"100195","DOI":"10.1016\/j.jhepr.2020.100195","article-title":"De novo synthesis of hepatitis B virus nucleocapsids is dispensable for the maintenance and transcriptional regulation of cccDNA","volume":"3","author":"Tu","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2012.12.008","article-title":"The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus","volume":"58","author":"Volz","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/hep.510290626","article-title":"Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy","volume":"29","author":"Tsiang","year":"1999","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0168-8278(02)00115-0","article-title":"Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B","volume":"37","author":"Wolters","year":"2002","journal-title":"J. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/jvh.13425","article-title":"What drives the dynamics of HBV RNA during treatment?","volume":"28","author":"Goncalves","year":"2021","journal-title":"J. Viral. Hepat."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1034\/j.1600-0676.2002.01579.x","article-title":"Viral dynamics in chronic hepatitis B patients during lamivudine therapy","volume":"22","author":"Wolters","year":"2002","journal-title":"Liver Int."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Bowden","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/hep.21282","article-title":"Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B","volume":"44","author":"Wursthorn","year":"2006","journal-title":"Hepatology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/j.1440-1746.2011.06766.x","article-title":"Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir","volume":"26","author":"Takkenberg","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.3748\/wjg.v21.i15.4644","article-title":"Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine","volume":"21","author":"Bowden","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1177\/135965350601100704","article-title":"One-Year Entecavir or Lamivudine Therapy Results in Reduction of Hepatitis B Virus Intrahepatic Covalently Closed Circular DNA Levels","volume":"11","author":"Wong","year":"2006","journal-title":"Antivir. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cgh.2013.01.026","article-title":"Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency","volume":"11","author":"Wong","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/jvh.12261","article-title":"Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss","volume":"21","author":"Zheng","year":"2014","journal-title":"J. Viral Hepat."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7150\/ijms.71737","article-title":"Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients","volume":"19","author":"Wang","year":"2022","journal-title":"Int. J. Med. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2016.08.022","article-title":"Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B","volume":"66","author":"Lai","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.31240","article-title":"Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients","volume":"73","author":"Huang","year":"2021","journal-title":"Hepatology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1038\/s41467-018-06318-7","article-title":"Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations","volume":"9","author":"MacParland","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"100278","DOI":"10.1016\/j.jhepr.2021.100278","article-title":"Single-cell RNA sequencing of human liver reveals hepatic stellate cell heterogeneity","volume":"3","author":"Payen","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Balagopal, A., Grudda, T., Ribeiro, R.M., Saad, Y.S., Hwang, H.S., Quinn, J., Murphy, M., Ward, K., Sterling, R.K., and Zhang, Y. (2020). Single hepatocytes show persistence and transcriptional inactivity of hepatitis B. J. Clin. Investig., 5.","DOI":"10.1172\/jci.insight.140584"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/infdis\/jiz607","article-title":"Single Hepatocyte Hepatitis B Virus Transcriptional Landscape in HIV Coinfection","volume":"221","author":"Balagopal","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1073\/pnas.0308478100","article-title":"Expansion and contraction of the hepatitis B virus tran-scriptional template in infected chimpanzees","volume":"101","author":"Wieland","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8+ T Cells Mediate Viral Clearance and Disease Pathogenesis during Acute Hepatitis B Virus Infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cbpa.2019.02.009","article-title":"Recent advances in the development of HBV capsid assembly modulators","volume":"50","author":"Nijampatnam","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41575-022-00700-z","article-title":"Nomenclature of HBV core protein-targeting antivirals","volume":"19","author":"Zoulim","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Taverniti, V., Ligat, G., Debing, Y., Kum, D.B., Baumert, T.F., and Verrier, E.R. (2022). Capsid Assembly Modulators as Antiviral Agents against HBV: Molecular Mechanisms and Clinical Perspectives. J. Clin. Med., 11.","DOI":"10.3390\/jcm11051349"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"104917","DOI":"10.1016\/j.antiviral.2020.104917","article-title":"Targeting the multifunctional HBV core protein as a potential cure for chronic hepatitis B","volume":"182","author":"Viswanathan","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/liv.14851","article-title":"HBV 2021: New therapeutic strategies against an old foe","volume":"41","author":"Testoni","year":"2021","journal-title":"Liver Int."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coviro.2018.04.004","article-title":"Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections","volume":"30","author":"Tu","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hep.32314","article-title":"Getting to HBV cure: The promising paths forward","volume":"76","author":"Fung","year":"2022","journal-title":"Hepatology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3350\/cmh.2022.0012","article-title":"RNA interference as a novel treatment strategy for chronic hepatitis B infection","volume":"28","author":"Hui","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/gutjnl-2020-322571","article-title":"Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5\/6 complex and silencing of the viral genome in vivo","volume":"71","author":"Allweiss","year":"2022","journal-title":"Gut"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Van den Berg, F., Limani, S.W., Mnyandu, N., Maepa, M.B., Ely, A., and Arbuthnot, P. (2020). Advances with RNAi-Based Therapy for Hepatitis B Virus Infection. Viruses, 12.","DOI":"10.3390\/v12080851"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.31008","article-title":"RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients with Chronic Hepatitis B Infection","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/gutjnl-2020-323445","article-title":"Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment","volume":"71","author":"Yuen","year":"2022","journal-title":"Gut"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","article-title":"Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB","volume":"77","author":"Yuen","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2020.01.032","article-title":"Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice","volume":"158","author":"Michler","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","article-title":"Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: A phase 2 randomized controlled trial","volume":"27","author":"Yuen","year":"2021","journal-title":"Nat. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients with Chronic HBV Infection Naive to Nu-cleos(t)ide Therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromo-some","volume":"122","author":"Belloni","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e02888-21","DOI":"10.1128\/mbio.02888-21","article-title":"CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants","volume":"13","author":"Martinez","year":"2022","journal-title":"Mbio"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"590989","DOI":"10.3389\/fcimb.2021.590989","article-title":"The Use of CRISPR\/Cas9 as a Tool to Study Human Infectious Viruses","volume":"11","author":"Lin","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Yang, Y.-C., and Yang, H.-C. (2021). Recent Progress and Future Prospective in HBV Cure by CRISPR\/Cas. Viruses, 14.","DOI":"10.3390\/v14010004"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.31695","article-title":"Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators","volume":"74","author":"Amin","year":"2021","journal-title":"Hepatology"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Kayesh, M.E.H., Kohara, M., and Tsukiyama-Kohara, K. (2021). Toll-Like Receptor Response to Hepatitis B Virus Infection and Potential of TLR Agonists as Immunomodulators for Treating Chronic Hepatitis B: An Overview. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910462"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Balsitis, S., Gali, V., Mason, P.J., Chaniewski, S., Levine, S.M., Wichroski, M.J., Feulner, M., Song, Y., Granaldi, K., and Loy, J.K. (2018). Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0190058"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhepr.2019.06.001","article-title":"HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection","volume":"1","author":"Huang","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhepr.2019.07.007","article-title":"Is PD-1 blockade a potential therapy for HBV?","volume":"1","author":"Feray","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/21645515.2019.1689745","article-title":"Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance","volume":"16","author":"Whitacre","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/jvh.13085","article-title":"Therapeutic vaccination for chronic hepatitis B: A systematic review and me-ta-analysis","volume":"26","author":"Lim","year":"2019","journal-title":"J. Viral. Hepat."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/cei.13614","article-title":"Therapeutic vaccination for treatment of chronic hepatitis B","volume":"205","author":"Cargill","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7774\/cevr.2020.9.1.1","article-title":"Hepatitis B vaccination and immunotherapies: An update","volume":"9","author":"Stasi","year":"2020","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"10808","DOI":"10.1038\/s41598-019-47149-w","article-title":"Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection","volume":"9","author":"Kosinska","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/gutjnl-2018-317725","article-title":"A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice","volume":"69","author":"Zhang","year":"2020","journal-title":"Gut"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1038\/mtna.2014.38","article-title":"The CRISPR\/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo","volume":"3","author":"Lin","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1038\/mtna.2014.68","article-title":"Targeting Hepatitis B Virus With CRISPR\/Cas","volume":"3","author":"Seeger","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.omtn.2020.03.005","article-title":"Permanent Inactivation of HBV Genomes by CRISPR\/Cas9-Mediated Non-cleavage Base Editing","volume":"20","author":"Yang","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Meng, C.Y., Sun, S., Liang, Y., Xu, H., Zhang, C., Zhang, M., Wang, F.S., Fu, Y.-X., and Peng, H. (2022). Engineered anti-PDL1 with IFNalpha targets both im-munoinhibitory and activating signals in the liver to break HBV immune tolerance. Gut.","DOI":"10.1136\/gutjnl-2022-327059"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Wang, L., Zhu, Q., Zhang, J.D., Zhang, Y., Ni, X., Xiang, K., Jiang, J., Li, B., Yu, Y., and Hu, H. (2022). Discovery of a first-in-class orally available HBV cccDNA inhibitor. J. Hepatol.","DOI":"10.1016\/j.jhep.2022.12.014"}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/11\/3\/600\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:43:45Z","timestamp":1760121825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/11\/3\/600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":114,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["microorganisms11030600"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms11030600","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,27]]}}}